 "Coronavirus vaccine")
The nod to Covaxin raises many eyebrows
The approval from India's drug regulator to Hyderabad-based Bharat Biotech's vaccine candidate Covaxin has raised many eyebrows. This report in The Quint highlights some of the questions being raised by medical experts.
The DCGI said that the expert panel of the CDSCO relied on safety and immunogenicity data submitted by the firm in animal species and on clinical trials that were conducted in around 800 subjects in phase 1, phase 2. The data presumably demonstrated that the vaccine is safe and provides a satisfactory immune response. However, the firm has shared this data publicly only
